Products for Research Use Only

Danazol

CAT: 0804-HY-B1029-01Size: 100 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-B1029-01Size:100 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Danazol inhibits the proliferation of cancer cell MDA-MB-231 and MCF-7 with IC50 of 65 µg/mL and 31 µg/mL. Danazol arrests the cell cycle at G1 phase, induces apoptosis in MDA-MB-231 through PKCα signaling pathway[1].
CAS Number
17230-88-5
UNSPSC
12352005
Hazard Statement
H312+H332, H361
Target
Apoptosis; PKC; Tyrosinase
Type
Reference compound
Related Pathways
Apoptosis; Epigenetics; Metabolic Enzyme/Protease; TGF-beta/Smad
Field of Research
Cancer; Endocrinology
Assay Protocol
https://www.medchemexpress.com/Danazol.html
Purity
99.70
Solubility
DMSO : 25 mg/mL (ultrasonic; warming; heat to 60°C) |Ethanol : 20 mg/mL (ultrasonic)
Smiles
C#C[C@]1(O)CC[C@@]2([H])[C@]3([H])CCC4=CC5=C(C=NO5)C[C@]4(C)[C@@]3([H])CC[C@@]21C
Molecular Formula
C22H27NO2
Molecular Weight
337.46
Precautions
H312+H332, H361
References & Citations
[1]Thomas GW, et al., Effects of danazol on endothelial cell function and angiogenesis. Fertil Steril. 2007 Oct;88 (4 Suppl) :1065-70.|[2]Chang TS, Lin JJ. Inhibitory effect of danazol on melanogenesis in mouse B16 melanoma cells. Arch Pharm Res. 2010 Dec;33 (12) :1959-65. |[3]Deka SJ, et al., Danazol has potential to cause PKC translocation, cell cycle dysregulation, and apoptosis in breast cancer cells. Chem Biol Drug Des. 2017 Jun;89 (6) :953-963.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Launched